Coordination Funds
协调基金
基本信息
- 批准号:174860066
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:德国
- 项目类别:Priority Programmes
- 财政年份:2010
- 资助国家:德国
- 起止时间:2009-12-31 至 2017-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
In July 2009, the Senate of the Deutsche Forschungsgemeinschaft (DFG of German Research Foundation) announced the establishment of a new Priority Program on “Epigenetic regulation of normal hematopoiesis and its dysregulation in myeloid neoplasia”. In May 2010, an international review panel selected 15 research projects for funding within the project. This program brings basic and clinical research in Germany together and supports highly interactive projects in epigenetic research as well as in the development of novel epigenetic therapies. The program has two co-coordinators, Dr. Michael Lübbert in Freiburg and Dr. Christoph Plass in Heidelberg and includes a coordinating central project which supports internal and international activities between the members of the central project. Here we request funds for continuation of the coordinating Central Project for Priority Program. These funds will support the coordinators of the project with three major tasks: Task 1 will be to coordinate the daily work and communication in the Priority Program. Task 2 will be to provide support to the coordinators in promoting scientific advances from the Program on a national as well as international level. Task 3 is devoted to equal opportunities for female scientists and single parents with children.
2009年7月,德国研究基金会参议院宣布设立一个新的优先方案,题为“骨髓瘤中正常造血及其失调的表观遗传调节”。2010年5月,一个国际审查小组选定了15个研究项目,供该项目供资。该计划将德国的基础和临床研究结合在一起,并支持表观遗传学研究以及新型表观遗传疗法开发方面的高度互动项目。该计划有两名共同协调员,弗赖堡的Michael Lübbert博士和海德堡的Christoph Plass博士,并包括一个协调中心项目,支持中心项目成员之间的内部和国际活动。在此,我们请求提供资金,以继续协调优先方案的中央项目。这些资金将支持项目协调员完成三项主要任务:任务1是协调优先项目的日常工作和沟通。任务2是支持协调员在国家和国际一级促进该计划的科学进步。任务3专门讨论女科学家和有子女的单亲的平等机会问题。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Professor Dr. Michael Lübbert, Ph.D.其他文献
Professor Dr. Michael Lübbert, Ph.D.的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Professor Dr. Michael Lübbert, Ph.D.', 18)}}的其他基金
Combined epigenetic therapy of acute myeloid leukemia: translational studies of in vivo induction of gene expression and DNA hypomethylation
急性髓性白血病的联合表观遗传学治疗:体内诱导基因表达和 DNA 低甲基化的转化研究
- 批准号:
172102549 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Priority Programmes
Funktionelle Rolle von Cytosin-Demethylierung in der transkriptionellen Regulation myeloischer Differenzierung
胞嘧啶去甲基化在骨髓分化转录调控中的功能作用
- 批准号:
5228002 - 财政年份:2000
- 资助金额:
-- - 项目类别:
Research Grants
Prospective randomized multicenter phase III trial of decitabine and Venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
地西他滨和维奈托克联合全反式维甲酸或安慰剂治疗不适合诱导化疗的急性髓系白血病患者的前瞻性随机多中心 III 期试验
- 批准号:
367848349 - 财政年份:
- 资助金额:
-- - 项目类别:
Clinical Trials